AU2002346859C1 - Macrolides containing pharmaceutical compositions - Google Patents

Macrolides containing pharmaceutical compositions Download PDF

Info

Publication number
AU2002346859C1
AU2002346859C1 AU2002346859A AU2002346859A AU2002346859C1 AU 2002346859 C1 AU2002346859 C1 AU 2002346859C1 AU 2002346859 A AU2002346859 A AU 2002346859A AU 2002346859 A AU2002346859 A AU 2002346859A AU 2002346859 C1 AU2002346859 C1 AU 2002346859C1
Authority
AU
Australia
Prior art keywords
compound
formula
amino
propanediol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002346859A
Other languages
English (en)
Other versions
AU2002346859B2 (en
AU2002346859A1 (en
Inventor
Josef Gottfried Meingassner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127341A external-priority patent/GB0127341D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002346859A1 publication Critical patent/AU2002346859A1/en
Publication of AU2002346859B2 publication Critical patent/AU2002346859B2/en
Application granted granted Critical
Publication of AU2002346859C1 publication Critical patent/AU2002346859C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2002346859A 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions Ceased AU2002346859C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0125443.2A GB0125443D0 (en) 2001-10-23 2001-10-23 Organic Compounds
GB0125443.2 2001-10-23
GB0127341.6 2001-11-14
GB0127341A GB0127341D0 (en) 2001-11-14 2001-11-14 Organic compounds
PCT/EP2002/011799 WO2003035068A1 (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Publications (3)

Publication Number Publication Date
AU2002346859A1 AU2002346859A1 (en) 2003-07-03
AU2002346859B2 AU2002346859B2 (en) 2006-03-02
AU2002346859C1 true AU2002346859C1 (en) 2008-07-10

Family

ID=26246689

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346859A Ceased AU2002346859C1 (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Country Status (19)

Country Link
US (1) US7259170B2 (enExample)
EP (1) EP1439838A1 (enExample)
JP (1) JP2005509634A (enExample)
KR (2) KR20090114483A (enExample)
CN (1) CN1307993C (enExample)
AU (1) AU2002346859C1 (enExample)
BR (1) BR0213463A (enExample)
CA (1) CA2458690C (enExample)
EC (1) ECSP045086A (enExample)
GB (1) GB0125443D0 (enExample)
HU (1) HUP0402108A3 (enExample)
IL (1) IL160973A0 (enExample)
MX (1) MXPA04003738A (enExample)
NO (1) NO20042074L (enExample)
NZ (1) NZ532412A (enExample)
PL (1) PL368533A1 (enExample)
RU (1) RU2321402C2 (enExample)
WO (1) WO2003035068A1 (enExample)
ZA (1) ZA200401711B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921934T2 (de) 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
AU664178B2 (en) * 1991-03-19 1995-11-09 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
GB9203636D0 (en) * 1992-02-19 1992-04-08 Lucas Ind Plc Fuel pumping apparatus
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO1994021642A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Macrocyclic amide and urea immunomodulators
US5590460A (en) * 1994-07-19 1997-01-07 Tessera, Inc. Method of making multilayer circuit
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
GB9521322D0 (en) 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ES2240868T3 (es) * 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
GB0003932D0 (en) 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
JP2004523275A (ja) 2000-12-22 2004-08-05 アバンテク バスキュラー コーポレーション 治療能力のある薬剤の送達

Also Published As

Publication number Publication date
MXPA04003738A (es) 2004-07-23
RU2321402C2 (ru) 2008-04-10
AU2002346859B2 (en) 2006-03-02
KR20090114483A (ko) 2009-11-03
CN1575173A (zh) 2005-02-02
HUP0402108A2 (hu) 2005-02-28
WO2003035068A1 (en) 2003-05-01
CN1307993C (zh) 2007-04-04
ECSP045086A (es) 2004-06-28
US7259170B2 (en) 2007-08-21
KR20040052250A (ko) 2004-06-22
CA2458690C (en) 2011-01-25
KR100978971B1 (ko) 2010-08-30
NZ532412A (en) 2006-01-27
PL368533A1 (en) 2005-04-04
ZA200401711B (en) 2004-10-21
CA2458690A1 (en) 2003-05-01
RU2004116067A (ru) 2005-04-20
NO20042074L (no) 2004-05-19
IL160973A0 (en) 2004-08-31
EP1439838A1 (en) 2004-07-28
HUP0402108A3 (en) 2008-02-28
BR0213463A (pt) 2004-11-09
US20040192716A1 (en) 2004-09-30
JP2005509634A (ja) 2005-04-14
GB0125443D0 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
CN1146411C (zh) 1,3-丙二醇衍生物的新用途
JP6077265B2 (ja) 自己免疫性疾患の処置剤
CA2905457A1 (en) Treatment of cataplexy
JP2012505257A (ja) 多発性硬化症治療のための組成物および方法
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
EP2326325B1 (en) Azetidine derivative for the treatment of peripheral neuropathies
CA3042493A1 (en) Combination therapy of cbd and copaxone
AU2002346859B2 (en) Macrolides containing pharmaceutical compositions
AU2002346859A1 (en) Macrolides containing pharmaceutical compositions
JP2008516961A (ja) 神経変性障害を処置することにおける使用のためのカルバメート化合物
EP2328571B1 (en) Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
MXPA00012248A (es) Incrementadores de acetilcolina.
JP2558147B2 (ja) 免疫性疾患治療剤
Nattero et al. Reserpine for migraine prophylaxis
JP2001508020A (ja) 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
HK1156229B (en) Azetidine derivative for the treatment of peripheral neuropathies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 FEB 2008.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 FEB 2008

MK14 Patent ceased section 143(a) (annual fees not paid) or expired